Femasys Inc.

NasdaqCM FEMY

Femasys Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -15.89 M

Femasys Inc. EBITDA is USD -15.89 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -34.25% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Femasys Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -11.83 M, a -19.04% change year over year.
Femasys Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -9.94 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: FEMY

Femasys Inc.

CEO	Ms. Kathy Lee-Sepsick M.B.A.
IPO Date	June 18, 2021
Location	United States
Headquarters	3950 Johns Creek Court
Employees	32
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Clinical Trials Cosmetics Medical Instruments Personal Care Pharmaceuticals

Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Key trends

Past 5 years